# TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery

> **NCT03881878** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 67 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** TAHP and AHP
- **DRUG:** TAHP plus AC and AHP

## Key facts

- **NCT ID:** NCT03881878
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-27
- **Primary completion:** 2022-10-31
- **Final completion:** 2022-10-31
- **Target enrollment:** 67 (ESTIMATED)
- **Last updated:** 2019-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03881878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03881878, "TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03881878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*